in P rats (Table 4) but needs to be tested in the other lines as well. Baclofen reduces ethanol self-administration under operant conditions in AA, P and sP rats (Table 4), although it has very modest effects in HAD1 and P rats under home-cage access conditions (KM Franklin, personal communication; but see Quintanilla et al., 2008 regarding positive findings in UChB rats under home-cage access conditions). Gabapentin increases ethanol intake in P and Wistar rats while inducing a very modest decrease in ethanol intake by HAD1 rats (KM Franklin, personal communication), but still needs to be tested in other rat lines. Amperozide, a 5HT2A antagonist, reduces ethanol intake in AA, HAD and P (Table 4) as well as FH/Wjd (Overstreet et al., 2007) rats. Findings with 5HT3 antagonists have shown promise in P and sP rats (Table 4), although unpublished work from our laboratory suggests this does not hold true for ondansetron itself (but see Overstreet et al., 2007 regarding positive findings in FH/Wjd rats). Inhibitors of the serotonin transporter decrease ethanol intake in HAD and P (Table 4) as well as UChB (Alvarado et al., 1990) and FH/Wjd (Overstreet et al., 2007) rats. Finally, antalarmin, a CRF1 antagonist, reduces
